Showing results (331-340 of 6,286) with videos related to

Sort By:
Pageof 629
Diabetes, Obesity & Metabolism|February 5, 2019
Generalizability of glucagon-like peptide-1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United StatesKristina S Boye, Matthew C Riddle, Hertzel C Gerstein, et al.
Diabetes, Obesity & Metabolism|January 24, 2019
Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney diseaseDavid M Charytan, Scott D Solomon, Peter Ivanovich, et al.
Diabetes, Obesity & Metabolism|January 31, 2019
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysisTadashi Toyama, Brendon L Neuen, Min Jun, et al.
Diabetes, Obesity & Metabolism|January 22, 2019
Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatmentEmilie H Zobel, Bernt J von Scholten, Bryan Goldman, et al.
Diabetes, Obesity & Metabolism|December 1, 2018
Sustained 52-week efficacy and safety of triple therapy with dapagliflozin plus saxagliptin versus dual therapy with sitagliptin added to metformin in patients with uncontrolled type 2 diabetesYehuda Handelsman, Chantal Mathieu, Stefano Del Prato, et al.
Diabetes, Obesity & Metabolism|December 21, 2019
Benefits of insulin degludec/liraglutide are maintained even in patients discontinuing sulphonylureas or dipeptidyl peptidase-4 inhibitors upon initiation of degludec/liraglutide therapy: A post hoc analysis of the DUAL II and DUAL IX trialsAndrej Janez, Petra Őrsy, Karolina Stachlewska, et al.
Diabetes, Obesity & Metabolism|December 21, 2019
Low-dose empagliflozin as adjunct-to-insulin therapy in type 1 diabetes: A valid modelling and simulation analysis to confirm efficacyBruce A Perkins, Nima Soleymanlou, Julio Rosenstock, et al.
Diabetes, Obesity & Metabolism|February 14, 2018
Alirocumab vs usual lipid-lowering care as add-on to statin therapy in individuals with type 2 diabetes and mixed dyslipidaemia: The ODYSSEY DM-DYSLIPIDEMIA randomized trialKausik K Ray, Lawrence A Leiter, Dirk Müller-Wieland, et al.
Diabetes, Obesity & Metabolism|March 9, 2018
Amodiaquine improves insulin resistance and lipid metabolism in diabetic model miceHoe-Yune Jung, Bobae Kim, Hye Guk Ryu, et al.
Diabetes, Obesity & Metabolism|March 9, 2018
Use and effectiveness of dapagliflozin in routine clinical practice: An Italian multicentre retrospective studyGian Paolo Fadini, Giancarlo Zatti, Ileana Baldi, et al.
Pageof 629